IGHE and small cell lung carcinoma: Similarly, SCLC patients also exhibited a significant decline in IgE levels after treatment, with the baseline median of 263.8 IU/ml (IQR: 145.5–481.3) decreasing to 204.1 IU/ml (IQR: 96.0–382.9) post-treatment, resulting in a median reduction of 59.7 IU/ml (IQR: 263.8–204.1; Z = -3.823, p < 0.001) (Figure 2).